The Drug Profile Record (cont'd)

Ric,
The information you got for me just in the bibliographic record is very helpful.

I would, however, like some data on the drug's development history, especially if it's in any stage of development in France. I had heard that there was some activity with this drug in Europe. Is that data available in this database too? If so, would you please get that information.

Great job!

To get the information Sharon wants we could pull up the record using Format 7, but I think I'll get the entire record in case she is interested in more about the drug. The full record retrieves an abstract and commercial, scientific, and patent summaries which might be useful.
Tip 2-11

I mentioned earlier that there are two sub-files in this database. We can separate the drug profile records from the R&D Focus News records and then search the status field for stages of development in a specified country. That should get us the information on the status of this drug in France.

We can also search for a specified phase of development anywhere in the world. That makes this database a good one for questions about international drug development status.

LATEST INFORMATION: 
27 February 2006: On 19 January 2006 Novartis reported that it 
has initiated a phase II trial of vatalanib in the USA in 
patients with age-related macular degeneration (AMD). The 
agent is a vascular endothelial growth factor receptor (VEGF-R) 
inhibitor that is also being evaluated in phase III trials in 
colorectal cancer patients and in phase I trials in patients 
with solid tumors. A regulatory filing for the treatment of 
colorectal cancer is planned for 2007.


CURRENT DEVELOPMENT STATUS: 

Highest Phase: Phase III (50) 

Development Phase/ 

Country/Indication: Phase 
III--Worldwide--colorectal cancer
Phase II--France--NSCLC
Phase II--Germany-- NSCLC
Phase II--USA--AMD
Phase II--USA--mesothelioma
Phase I--USA-- solid tumor
Phase I--Europe--solid tumor
Phase I--Europe--ovarian cancer 


Abstract: 
DEC 2006: Bayer acquires Schering AG as a wholly-owned 
subsidiary to form Bayer Schering.
  JUL 2005: Phase II, USA (AMD).
  MAR 2005: Phase II, France, Germany (NSCLC).
  JAN 2005: Phase I/II, USA, Europe (solid tumor, including 
breast, ovarian, prostate, pancreatic cancer and NSCLC). 
Agreement between Schering AG and Novartis modified.
  JUL 2003: Phase II, USA (malignant mesothelioma).
  JAN 2003: Phase III, USA, Europe (colorectal cancer).
  DEC 2001: Preclinical, USA (multiple myeloma).
  APR 2001: Phase II, USA, Europe.
  APR 2000: Phase I, USA, Europe.
  OCT 1999: Phase I, Switzerland.
  1995: Agreement between Schering AG and Novartis.
  FEB 1997: Priority product patent application filed in 
Switzerland, by Novartis.

This part of the record also identifies other countries where vatalanib is being marketed. As is the case with other drugs, they are also using vatalanib for more than just various forms of cancer. It is currently in Phase ii clinical trials for age-related macular degeneration (AMD) in the U.S.

Go to the next page.

2-6